Bristol Myers Squibb and 2seventy bio Provide Update on KarMMa-9 …
WEB2 days ago · We designed KarMMa-9 based on positive data from cohort 2c of the KarMMa-2 trial, which demonstrated a favorable benefit/risk profile. Bristol Myers Squibb and 2seventy bio have made the difficult decision to discontinue enrollment in the Phase 3 KarMMa-9 study investigating Abecma (idecabtagene vicleucel) with lenalidomide maintenance versus ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · Warnings and Precautions: Early Death: In KarMMa-3, a randomized (2:1), controlled trial, a higher proportion of patients experienced death within 9 months after randomization in the ABECMA arm ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025. Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 ...
KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly …
WEB2 days ago · The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment. News OncClub All Oncology News Pipeline Report
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · These statements include, but are not limited to: statements about the discontinuation of the ongoing Phase 3 KarMMa-9 study, including the potential cost savings; statements regarding expected ABECMA (ide-cel) ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to …
KarMMa-9: Idecabtagene vicleucel plus lenalidomide for the …
WEBJun 4, 2024 · KarMMa-9 trial will compare the efficacy and safety of ide-cel and lenalidomide as a combination therapy vs lenalidomide alone in patients with NDMM who experience an incomplete response to ASCT. Ide-cel combined with standard-of-care maintenance therapy is expected to improve clinical outcomes and prolong PFS in …
2seventy bio Announces Plans to Initiate KarMMa-9 Study of …
WEBSep 7, 2022 · In the KarMMa study, 41% of patients (52/127) experienced prolonged Grade 3 or 4 neutropenia and 49% (62/127) experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Month 1 ...
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb …
WEBApr 5, 2024 · Among patients who received Abecma in the KarMMa and KarMMa-3 studies (n=349), any grade CRS occurred in 89% of patients, including Grade > 3 CRS in 7% of patients, and three cases (0.9%) of Grade 5 CRS reported. The median time to onset of CRS was 1 day (range: 1-27 days), and the median duration of …
KarMMa-9 - Bristol Myers Squibb Myeloma Clinical Trials
WEBKarMMa-9. Phase 3 Clinical Trial Comparing the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance to Approved Lenalidomide Maintenance Alone in Patients with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Stem Cell Transplant
- Some results have been removed
Skip to content